Diabetic macular edema, resulting from increased microvascular permeability, is the most prevalent cause of vision loss in diabetes. The mechanisms underlying this complication remain poorly understood. In the current study, diabetic vascular permeability (blood-retinal barrier breakdown) is demonstrated to result from a leukocyte-mediated Fas-FasL-dependent apoptosis of the retinal vasculature. Following the onset of streptozotocin-induced diabetes, FasL expression was increased in rat neutrophils (P<0.005) and was accompanied by a simultaneous increase in Fas expression in the retinal vasculature. Static adhesion assays demonstrated that neutrophils from diabetic, but not control, rats induced endothelial cell apoptosis in vitro (P<0.005). The latter was inhibited via an antibody-based FasL blockade (P<0.005). In vivo, the inhibition of FasL potently reduced retinal vascular endothelial cell injury, apoptosis, and bloodretinal barrier breakdown (P<0.0001) but did not diminish leukocyte adhesion to the diabetic retinal vasculature. Taken together, these data are the first to identify leukocyte-mediated FasFasL-dependent retinal endothelial cell apoptosis as a major cause of blood-retinal barrier breakdown in early diabetes. These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy.
D
iabetic retinopathy, the leading cause of new-onset blindness among working-age Americans (1) , is characterized by early retinal microvascular dysfunction leading to blood-retinal barrier breakdown. The increased adhesion of leukocytes to the retinal microvasculature is one of the earliest changes observed in the retina, occurring before clinically detectable pathology (2) . Leukocyte adhesion coincides with the development of blood-retinal barrier breakdown, capillary nonperfusion, and endothelial cell injury and death (2) (3) (4) (5) . The upregulation of adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-1), on the endothelium and the ß2 integrin CD18 on leukocytes is involved in these events (2, 6) . The antibody-based inhibition of ICAM-1 or CD18 prevents diabetic retinal leukocyte adhesion and blood-retinal barrier breakdown (2, 6, 7) . The inhibition of leukocyte adhesion also suppresses endothelial cell injury and death (7) , although the mechanisms responsible for leukocytemediated endothelial cell death remain unclear, as do the molecular mechanisms of blood-retinal barrier breakdown.
Several members of the tumor necrosis factor (TNF) receptor superfamily, which includes Fas (Apo-1/CD95) and the death receptors for TRAIL/Apo-2L (DR4 and DR5), are involved in cellmediated cytotoxicity. Upon binding, their respective ligands (FasL and TRAIL), Fas, and DR4/DR5 recruit and activate zymogen forms of the cysteine protease caspases, particularly procaspase-8 (8) or procaspase-10 (9). These molecules proteolytically activate downstream (executional) caspases, such as caspase-3, whose enzymatic activity results in apoptotic death. FasL expression is limited to cells of the immune system (10) and a few immune-privileged sites (11) . In contrast, TRAIL is expressed in a wide range of normal fetal and adult tissues (12) but usually induces apoptosis only in transformed or malignant cells.
Because retinal vascular endothelial cells express both Fas and DR4/DR5, which might be activated by FasL and/or TRAIL expressing leukocytes, we evaluated the mechanistic role of these molecules in diabetes-induced, leukocyte-mediated retinal vascular dysfunction. In this study, we demonstrate that the interaction between vascular cells of the retina and diabetesinduced FasL expression on the neutrophil surface mediate diabetes-induced endothelial cell damage, apoptosis, and retinal vascular permeability. In contrast, the DR4/DR5/TRAIL system does not appear to play a major role in this regard. These data suggest a mechanistic role for FasFasL in the development of diabetic retinopathy and macular edema and imply that targeting of the Fas-FasL system may prove beneficial in treating the retinal complications of diabetes.
MATERIALS AND METHODS

Antibodies
Neutralizing anti-human Fas monoclonal antibody (mAb) NOK-2 (Pharmingen, San Diego, CA), anti-human TRAIL (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-human DR4 and DR5 antibodies (R&D Systems, Minneapolis, MN) were used for in vitro experiments. The anti-rat MFL4 antibody against Fas ligand (Armenian hamster IgG) and control antibody (Armenian hamster anti-TNP IgG) were used for in vivo experiments and were purchased from Pharmingen. Antibodies were free of endotoxin as determined by the manufacturer.
Animals
Male Long-Evans rats weighing ∼200 g were used in all experiments. All protocols abided by the ARVO statement on the Use of Animals in Ophthalmology and Vision Research and were approved by the Animal Care and Use Committee of Children's Hospital. The animals were fed standard laboratory chow and were allowed free access to water in an air-conditioned room with a 12-h light-dark cycle. Except as noted, the animals were anesthetized with ketamine (80 mg/kg; Ketalar, Parke-Davis, Morris Plains, NJ) and xylazine (4 mg/kg; Rompun, Harver-Lockhart, Morris Plains, NJ) before all experimental manipulations.
Induction of diabetes
Following a 12-h fast, animals received a single 60 mg/kg i.p. injection of streptozotocin (Sigma, St. Louis, MO) in 10 mM sodium citrate buffer, pH 4.5. Age-matched on-diabetic animals were also fasted and received citrate buffer alone. Twenty-four hours later, animals with blood glucose levels >250 mg/dl were considered diabetic. In vivo experiments were performed 2 wk following the induction of diabetes. The diabetic state was confirmed by blood glucose measurement again before experimentation. All in vivo experiments were performed in a masked fashion.
Systemic treatment with anti-FasL antibody
Anti-rat MFL4 antibody against Fas ligand or control antibody was administered as a single i.p. injection in 2-wk diabetic animals at a concentration of 1 mg/kg 48 h before they were killed.
Neutrophil isolation
Peripheral blood was obtained from diabetic and control rats anesthetized with 50 mg/kg pentobarbital via heart puncture with a 16-gauge EDTA flashed needle. Neutrophils were isolated from whole blood by density gradient centrifugation with NIM2 (neutrophil isolation media, Cardinal Associates, Santa Fe, NM) according to the manufacturer's instructions. The red blood cells were lysed with a hypotonic solution (E-Lyse, Cardinal Associates). The preparations contained >91% neutrophils, as determined by eosin and methylene blue staining (Leukostat Staining System, Fisher Scientific, Pittsburgh, PA). Cells were resuspended in RPMI medium and used immediately after separation for either adhesion experiments or FACS analysis.
Endothelial and leukocyte coculture
Human dermal microvascular endothelial cells for leukocytes studies were isolated as previously described (13) and cultured in EBM 131(Clonetics, San Diego, CA), 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT), 1× gentamycin, penecillin, streptomycin, and 2 ng/ml bFGF in 5% CO 2 . The endothelial phenotype was confirmed by CD31 staining (FITCcoupled anti-human CD31 mAb, Pharmingen). Passages 14-18 were used for the experiments. All cells were cultured at 37 o C in 5% CO 2 /95% air, and media were changed every 2-3 days. For the experiments, cells were seeded onto gelatin-coated plates at a concentration of 2×10 5 cells/well and stimulated with 30 ng/ml recombinant human tumor necrosis factor α (TNF-α; Genzyme, Cambridge, MA). The cells expressed classical endothelial markers, including von Willebrand factor and platelet endothelial cell adhesion molecule 1 (PECAM-1, CD31) (data not shown). Unstimulated neutrophils from normal and diabetic rats were resuspended at 2×10 6 cells/ml in RPMI/5% FCS and incubated for 10 min at 37°C with 1 µM of the fluorescent marker 2'7'-bis-(2 carboxyethyl)-5 carboxyfluorescein acetoxymethyl ester (Molecular Probes, Eugene, OR) in 0.5% dimethyl sulfoxide (vehicle). Fluorescent-labeled cells were washed and then incubated (2×10 6 cells/ml, 50 µl per well) with endothelial monolayers for 4 h, after which the neutrophils were removed and the endothelial monolayer washed. Cell death was assayed as described later. To determine the role of the Fas-FasL and DR4/DR5/TRAIL system in endothelial cell apoptosis, we preincubated leukocytes with neutralizing antibodies against FasL or TRAIL. Endothelial cells were incubated with neutralizing antibodies for Fas or DR4/DR5 1 h before coculture.
Terminal transferase dUTP nick-end labeling (TUNEL)
Free 3'OH DNA termini were labeled using the TUNEL procedure according to the manufacturer's recommendations (Intergen, Burlington, MA). In short, adherent, labeled leukocytes and endothelial cells were fixed in 1% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, for 10 min at room temperature. DNA fragments were labeled with a digoxigeninnucleotide and then allowed to bind an anti-digoxygenin antibody conjugated to a rhodamine reporter molecule. Apoptotic cells were detected using a CD-330 charge-coupled device (CCD) camera (Dage-MIT, Michigan, IN) attached to a Leica MZ FLIII microscope (Leica Microsystems, Deerfield, Il). The images were captured on an Apple (Cupertino, CA) G4 Computer and analyzed using Openlab software (Improvision, Lexington, MA). The images were resolved at 624×480 pixels and converted to tagged information file format (.tiff) files. Apoptotic endothelial cells exhibited red (rhodamine) fluorescence, whereas apoptotic leukocytes demonstrated double labeling and appeared yellow. The number of apoptotic cells per visual field was counted in a masked fashion and divided by the number of adherent leukocytes. A minimum of 10 fields each in three separate experiments was analyzed per condition.
Flow cytometry
Surface expression of TRAIL and FasL on rat neutrophils from nondiabetic 1-wk and 6-month diabetic animals was determined using flow cytometry as previously described (14) . Purified neutrophils were resuspended in RPMI medium containing 5% heat-inactivated bovine serum and 20 µg/ml anti-FasL or anti-TRAIL antibodies and incubated for 1 h at room temperature. After three washes with RPMI medium, the cells were incubated at 25 o C for 15 min with FITCcoupled secondary antibodies and counterstained with phycoerythrin (PE)-coupled mAb to CD45. Neutrophils incubated with FITC-coupled secondary antibody alone and the PE-coupled mAb to CD45 were used as controls. The cells were then washed with PBS and incubated with 1 mg/ml propidium iodide (PI; Molecular Probes, Eugene, OR) to identify dead or injured cells. After centrifugation for 5 min at 500g, the cells were resuspended in 300 ml PBS and surface fluorescence was analyzed with a FACSscan (Becton Dickinson, San Jose, CA). Vital neutrophils were gated manually on the basis of their characteristic foreword and side lightscattering properties. Results are expressed as percent of all neutrophils expressing antigen.
Immunohistochemical localization of Fas in retina
Parafin sections from 2-wk diabetic animals and nondiabetic control rats were double labeled for CD31 and Fas. In brief, sections were deparafinized, rehydrated through a series of ethanols, microwaved for 10 min in Dako(Carpinteria, CA) antigen retrieval Solution, and then incubated for 1 h in a buffer containing 1% BSA and 0.1% Tween 20 in PBS. The sections were subsequently incubated with an anti-CD31 monoclonal antibody (Pharmingen) at a concentration of 1:100 overnight at 4°C. The following day, the sections were briefly washed in PBS containing 0.1% Tween 20 and incubated with an anti-fas polyclonal antibody (Santa Cruz Biotechnology) at a concentration of 1:100 overnight at 4°C. The following day, the sections were washed as described previously and incubated with an rhodamine conjugated anti-rabbit antibody at a concentration of 1:200 in 1% BSA and 0.1% Tween 20 in PBS for 1 h at room temperature. After washes, staining was observed under a fluorscence microscope.
DNA fragmentation ELISA
Cellular DNA fragmentation ELISA was used to quantitatively determine cell death (Roche Diagnositics, Mannheim, Germany). This ELISA detects BrdU-labeled DNA fragments in cell lysates. After 2 w of diabetes, animals received a single i.p. injection of 1 mg/kg anti-FasL or an isotype-matched control antibody. Twenty-four hours later, the animals received a single i.p. injection of 20 mg/kg BrdU. Retinae were then excised 24 h after injection of the BrdU, lysed in buffer (4 M urea,100 mM Tris, 20 mM NaCl, 200 mM EDTA, pH 7.4), and incubated with 4 mg/ml proteinase K at 55 o C. Fragments of genomic DNA were isolated using the Apoptotic DNA ladder kit (Boehringer Mannheim) according to the manufacturer's instructions and finally eluted in 100 ul of elution buffer per retina. The amount of fragmented DNA that corresponded to each eluate, and therefore to each retina, was subsequently quantified using the DNA fragmentation ELISA (Boehringer Mannheim) according to the manufacturer's instructions. Photometric readings were obtained at 450 nm, and results are expressed as percent of the nondiabetic value.
Enzymatic activity of caspase 3 and caspase 8
The activity of caspases 3 and 8 was measured via the enzymatic conversion of a specific substrate. In brief, retinae were lysed in a buffer containing 20 mmol PIPES, 100 mmol NaCl, 10 mmol DTT, 1 mmol EDTA, 0.1% CHAPS, and 10% sucrose, pH 7.2. After centrifugation of the homogenates at 13,000 rpm for 10 min, 40 µl aliquots of the supernatants were pipetted into 96-well plates. Excess amounts (80 µl) of caspase 8 (Bachem Biochemica GmbH, Heidelberg, Germany) or caspase 3 substrate (Alexis Biochemicals, Grünberg, Germany) were added to the supernatants. The reaction product was quantified via fluorophotometry on a plate reader (Beckmann, Hamburg, Germany) at 480 nm after 1, 2, 5, and 15 min (caspase 3) or 1, 60, 120, and 180 min (caspase 8). The results were normalized to total protein per sample as determined by the Bradford assay (Bio-Rad, Munich, Germany).
Measurement of blood-retinal barrier breakdown
Rats with 2-wk-duration diabetes were anesthetized, and Evans blue dye (45 mg/kg) was injected through the tail vein. After 120 min, the chest cavity was opened and rats were perfused for 2 min at a physiological pressure via the left ventricle with 0.05 M, pH 3.5, citrate-buffered paraformaldehyde (1% wt/vol; Sigma). A pH of 3.5 was used to optimize binding of Evans blue to albumin (15) , and the perfusion solution was warmed to 37 o C to prevent vasoconstriction. Immediately following perfusion, both eyes were enucleated and bisected at the equator. The retinae were carefully dissected and thoroughly dried in a Speed-Vac (Savant, St. Paul, MN) for 5 h. The dry weight was used to normalize the quantitation of Evans blue leakage. Evans blue was extracted by incubating each retina in 120 µl formamide (Sigma) for 18 h at 70 o C. The supernatant was filtered through Ultrafree-MC tubes (30,000 NMWL UFC3LTK00, Millipore, Bedford, MA) at 3000 rpm for 2 h, and 60 µl of the filtrate were used for triplicate spectrophotometric measurements (Du-640, Beckman, Fullerton CA). Each measurement occurred over a 5-s interval, and all sets of measurements were preceded by evaluation of known standards. The background-subtracted absorbance was determined by measuring each sample at 620 nm (the absorbance maximum for Evans blue in formamide) and 740 nm (the absorbance minimum). The concentration of dye in the extracts was calculated from a standard curve of Evans blue in formamide. Blood-retinal barrier breakdown was calculated using the following equation, with results being expressed in plasma (µl) × retina dry weight (g)
Evans blue (µg)/retina dry weight (g) ______________________________
Time-averaged Evans blue concentration (µg)/plasma (µl) × circulation time (h)
Results were expressed as percent of the nondiabetic value.
Retinal leukostasis quantitation
Deep anesthesia was induced with 50 mg/kg sodium pentobarbital. The chest cavity was opened, and the left ventricle was entered with a 14-gauge perfusion canula fixed to a vessel clamp, carefully avoiding ventricular obstruction. The right atrium was opened with a 12-gauge needle to achieve outflow. With the heart providing the motive force, 250 ml/kg PBS was perfused to clear erythrocytes and nonadherent leukocytes. Fixation was then achieved via perfusion with 1% paraformaldehyde and 0.5% glutaraldehyde at a pressure of 100 mm Hg. At this point, the heart stopped. A systemic blood pressure of 100 mmHg was maintained by perfusing a total volume of 200 ml/kg over 3 min. The inhibition of nonspecific binding with 1% albumin in PBS (total volume, 100 ml/kg) was followed by perfusion with FITC-coupled Concanavalin A lectin (20 µg/ml in PBS, pH 7.4; total concentration, 5 mg/kg body weight) (Vector Labs, Burlingame, CA). The latter stained adherent leukocytes and the vascular endothelium. Lectin staining was followed by 1% BSA/PBS perfusion for 1 min and PBS perfusion alone for 4 min to remove excess Concanavalin A (7). The retinas were flat mounted in a water-based fluorescence antifading medium (Fluoromount, Southern Biotechnology, Birmingham, AL) and imaged via fluorescence microscopy (Zeiss Axiovert, FITC filter). Only whole retinas in which the peripheral collecting vessels of the ora serrata were visible were used for analysis. Leukocyte location was scored as being either arteriolar, venular, or capillary. The total number of adherent leukocytes per retina was counted. All experiments were performed in a masked fashion.
PI labeling in vivo
Dead and injured endothelial cells were labeled in vivo using PI (Molecular Probes). Following the induction of deep anesthesia with 50 mg/kg i.p. sodium pentobarbital, PI (1 mg/ml in PBS) was injected i.v. via the tail vein at a concentration of 5 µmol/kg (0.668 ml/200 mg body weight). After 20 min, fixation by intracardiac perfusion and labeling with Concanavalin A-lectin was performed as described previously. Retinal flat mounts were examined by fluorescence microscopy as described previously. Labeled endothelial cells were distinguished from surrounding cells, especially pericytes, by distinct cellular outline and nuclear shape of the endothelial cells. All experiments were performed in a masked fashion
TUNEL histology
TUNEL was performed with horseradish peroxidase detection in micrometer sections from formalin-fixed paraffin-embedded retinas. Whole eyes from normal and diabetic rats treated either with the control or the anti-FasL antibody were fixed in 4% paraformaldehyde overnight at 4 o C. The TUNEL staining was performed as previously described (16) .
Detection of apoptosis-related enzymatic activity
Cytokeratin 18 is altered in early apoptotic events and is present in endothelial cells (17, 18). The M30 CytoDeath antibody is a monoclonal mouse IgG2b antibody that binds to a formalinresistant epitope of the cytokeratine 18 (CK18), a cytoskeletal protein exposed after caspase is cleaved. Immunoreactivity of the M30 antibodies is confined to the cytoplasma of apoptotic cells. Consequently, the M30 antibody allows reliable determination of caspase-related enzymatic activity early in the course of apoptosis. The M30 CytoDeath immunoreactivity was evaluated in formalin-fixed paraffin-embedded tissue sections of normal rats and diabetic rats that received either the anti-FasL or the isotype-matched control antibody. In brief, 5 µm paraffin sections were deparaffinized, rehydrated, microwaved for 5 min in Dako antigen retrieval, treated for 30 min in methanol containing 0.5% H 2 O 2 , and then incubated for 1 h in incubation buffer (PBS containing 1% BSA and 0.1% Tween 20). The M30 CytoDeath antibody was applied for 1 h at room temperature at a 1:50 dilution in incubation buffer. The sections were subsequently washed in PBS containing 0.1% Tween 20 and incubated with an anti-fluorescein-POD antibody (Boerhinger Mannheim) according to the manufacturer's instructions. The peroxidase reaction was developed with DAB, and the slides were counterstained with hematoxylin.
Statistical analysis
All results are expressed as the mean ±SD. Student's t test was used for populations with normal distribution and equal variance. The in vivo data were analyzed by Whitney-Mann U test, with post hoc comparisons tested using Fisher's protected least significant difference procedure. Differences were considered statistically significant when P<0.05.
RESULTS
Diabetic neutrophils induce endothelial cell apoptosis in vitro through Fas-FasL
To determine whether diabetic neutrophils preferentially induce endothelial cell apoptosis, neutrophils derived from nondiabetic and 1-wk, 6-wk, or 6-month diabetic animals were evaluated using the leukocyte/endothelial coculture assay described in Materials and Methods (Fig. 1) . As shown in Figures 1A-1C , the number of TUNEL-positive endothelial cells per adherent neutrophil increased from 0.23±0.11 for nondiabetic leukocytes to 1.48±0.41 (P<0.001), 4.53±1.94 (P<0.001), and 4.46±2.11 (P<0.05) for the 1-wk, 6-wk or 6-month diabetic neutrophils, respectively (P<0.001). For these experiments, coincubation time was 4 h. A timecourse analysis revealed that at 16 h, the proportion of apoptotic endothelial cells was unchanged between the diabetic and nondiabetic neutrophils; however, the absolute numbers were greater (data not shown).
To confirm whether Fas and FasL were involved in mediating the increased apoptosis, endothelial cells were preincubated for 1 h with neutralizing antibodies against Fas, DR4, and DR5 (Fig. 1D) 
Diabetes increases Fas and FasL expression in vivo
To determine whether diabetes-induced expression of FasL on leukocytes provided a source of initiation of Fas-FasL-mediated apoptosis, leukocyte cell surface expression of FasL and TRAIL was determined by FACS analysis. Neutrophils were isolated from nondiabetic rats and rats with diabetes of 1-wk or 6-month duration ( Fig. 2A) . The expression of FasL and TRAIL was not significantly different from control antibody in nondiabetic animals (4.2±2.7%). In contrast, neutrophil FasL expression was increased to 28.5±3.6% (P<0.005) after 1 wk of diabetes and further increased to 36.2±4.3% (P<0.001) after 6 months of diabetes. The expression of TRAIL did not significantly change even after 6 months of disease.
To determine whether diabetes increased Fas expression in the retina and whether this expression colocalized with retinal vascular endothelial cells, Fas expression was evaluated using immunohistochemistry in paraffin sections derived from 2-wk diabetic and control rats (Fig. 2B) .
Retinal endothelial cells were identified using an antibody to CD31. Fas staining was substantially increased in diabetic rats compared with that of nondiabetic rats, in which staining was minimal. CD31 staining of endothelial cells was evident in both diabetic and nondiabetic animals. The majority of diabetes-induced Fas staining colocalized with areas of CD31 staining.
Fas-induced retinal endothelial cell injury, apoptosis, and death in vivo
To investigate the in vivo role of Fas and FasL in mediating leukocyte-induced retinal endothelial cell death, we assessed the effect of a neutralizing anti-FasL antibody on retinal endothelial injury by using a PI incorporation assay (Fig. 3A, 3B ). As previously demonstrated (7), diabetic retina exhibited a marked increase in PI-labeled cells that were mainly located in clusters, often adjacent to adherent leukocytes (P<0.0005). In contrast, the total number of PI-labeled endothelial cells per retina in eyes of animals treated with neutralizing anti-FasL antibody was suppressed (n=14, 11±7.76 vs. 96.14±15.41; P<0.0001) compared with animals receiving control antibody.
To identify whether, and localize where, apoptosis was occurring under these conditions, formalin-fixed paraffin-embedded retinal sections were stained using TUNEL and M30 CytoDeath antibody (Fig. 3C-3H ). TUNEL-positive cells showed nuclear staining, whereas M30-positive cells stained cytoplasm. In diabetic animals, TUNEL and M30 staining was readily observed and positive cells were predominantly located in the ganglion cell layer and in the vascular endothelium. When retinal vessels were evident in these routine histologic sections, there was associated staining. In contrast, nondiabetic animals showed little staining anywhere in the retina. When diabetic animals were treated with anti-FasL antibody, TUNEL and M30 staining was attenuated.
The increase in M30 staining in the diabetic retinae was consistent with the involvement of caspases in the process of apoptotic cell death. During apoptosis, caspases are activated in a hierarchical manner and serve to cleave the structural and functional proteins needed for cell survival. The ability of caspases to cleave their specific substrates was tested directly in retinal lysates. In comparison to nondiabetic retinae, the substrate conversion rate for caspase 3 was 2. 
Fas-FasL and diabetes-induced blood-retinal barrier breakdown in vivo
To quantitate apoptotic cell death in the retina, we used a modified ELISA for fragmented DNA (Fig. 4A) . The DNA fragmentation ELISA measured total apoptosis in the retina. After 2 wk of diabetes, fragmented DNA had increased by almost 13.84±0.41-fold (P<0.005) compared with nondiabetic retina (1.0±0.15-fold). Systemic treatment with anti-FasL antibody reduced fragmented retinal DNA to nearly nondiabetic levels (1.22±0.82-fold; P<0.0005) whereas control IgG antibody had no significant attenuating effect (14.64±0.64-fold).
To determine whether the Fas-FasL system was involved in mediating diabetic blood-retinal barrier breakdown, the Evans blue assay was performed in nondiabetic and 2-wk diabetic rats 48 h after treatment with control or anti-FasL neutralizing antibodies (Fig. 4B) . Two weeks of diabetes increased blood-retinal barrier breakdown 2. 
Fas-FasL blockade does not decrease leukocyte adhesion in vivo
To determine whether the antipermeability effects observed with the neutralizing FasL antibody were due to the inhibition of leukocyte adhesion in the retinal vasculature of diabetic animals (Fig. 5) , Concanavalin A lectin-staining was used as previously described (7). The total number of adherent leukocytes per retina was not significantly suppressed in the diabetic animals treated with the neutralizing anti-FasL antibody (n=14, 145.54±20.3 vs. 190.23±20.2; P>0.05) compared with diabetic animals treated with the control antibody.
DISCUSSION
Increased leukocyte adhesion has been shown to correlate spatially and temporally with endothelial cell injury and death in the diabetic rat retina (2, 7). Note that Fas-FasL-mediated cell death has also been demonstrated in the pathogenesis of islet cell death in autoimmune diabetes (19) . In current studies, the mechanistic role of the Fas-FasL and DR4/DR5/TRAIL pathways in diabetes-induced, leukocyte-mediated retinal endothelial cell death and blood-retinal barrier breakdown was investigated. The data demonstrate that the surface expression of FasL on leukocytes is increased by diabetes and that these leukocytes are capable of inducing Fasmediated endothelial cell injury, apoptosis, and blood-retinal barrier breakdown.
The probable involvement of leukocytes in initiating Fas-mediated retinal endothelial cell death under diabetic conditions is supported by several observations. Leukocytes expressed higher surface levels of FasL with increasing duration of diabetes. Incubation of diabetic leukocytes with microvascular endothelial cell cultures resulted in a marked increase in TUNEL staining that was blocked by either leukocyte pretreatment with anti-FasL or endothelial cell pretreatment with anti-Fas. Although it is possible that cross-species differences may have affected the results obtained in vitro, similar results were obtained in vivo with rat leukocytes and rat retinal endothelium, confirming the relevance of the findings. In vivo, adherent leukocytes were more prevalent in the diabetic retinal vasculature. Endothelial cell injury and apoptosis was observed in association with adherent intravascular leukocytes and was suppressed via anti-FasL antibodybased blockade. Although it has been previously hypothesized that Fas-FasL may influence the adhesiveness of leukocytes to target cells (20), we found that the administration of anti-FasL antibody in diabetic rats did not significantly alter leukocyte adhesiveness to the retinal vascular endothelium. These data suggest that although Fas-FasL interactions are responsible for inducing endothelial apoptosis and death, they are not primarily responsible for intravascular leukocyte adhesion.
The up-regulation of leukocyte FasL could potentially be mediated by various cytokines altered in diabetes. Interferon-α, IL-4, TNF-α, and IL-1β all increase FasL expression (21) , possibly as the result of NF-kB activation and its interaction with kB binding elements in the promoter of the FasL gene (22) . Interestingly, TRAIL expression is not altered by interferon-α (23) . The relative specificity of Fas pathway involvement as opposed to that of the TRAIL system was documented by the absence of a significant change in leukocyte surface expression of TRAIL and the inability of anti-TRAIL preincubation of leukocytes or anti-DR4/DR5 preincubation of endothelial cells to reduce leukocyte-induced endothelial cell apoptosis. For these reasons, in vivo blockade experiments were not pursued.
Our data suggest that injury and apoptosis occur early in the course of diabetes and occur also in nonendothelial cells such as retinal ganglion cells and astrocytes. Mizutani et al. noted accelerated death of endothelial cells in the retinas from diabetic patients (24) , and Barber et al. demonstrated increased neural cell death as early as 1 month after the induction of diabetes in the rat (25) . The lethal nature of the leukocyte-endothelial interaction is supported in this study by several findings. First, PI uptake specifically labeling injured and/or dead endothelial cells was observed as early as 1 wk following the onset of streptozotocin-induced diabetes, as noted previously (7). Second, apoptosis was detected via both TUNEL staining and caspase activity, as determined by the immunoreactive detection of cryptic epitopes (CytoDeath antibody). Third, cell death in the diabetic retina was confirmed by increases in total fragmented DNA.
The marked effect of the Fas-and FasL-neutralizing antibodies on in vitro and in vivo endothelial cell viability strongly suggests that direct contact between FasL-expressing leukocytes and Fasexpressing endothelial cells triggers Fas-FasL-mediated apoptosis. Myeloperoxidase levels in the rat neutrophils were not altered following exposure to the anti-FasL antibody (data not shown).
During inflammation, TNF-α and VEGF induce endothelial cell down-regulation of FasL and up-regulate Fas and adhesion molecules such as ICAM-1 (26) . This down-regulation of FasL in the endothelium, combined with leukocytes in diabetes that are less susceptible to various death stimuli (27) , could result in a relative increase in surviving leukocytes in immunopriveleged areas such as the retina. In addition, the converse up-regulation of adhesion molecules and Fas on the endothelium and increases in FasL on the leukocytes could function together to drive the balance toward significantly increased leukocyte-induced endothelial death. In vivo, this effect might be mediated by circulating factors such as VEGF, TNF-α, or oxidative stress. Indeed, it has been shown that the oxidized form of LDL (Low density lipoproteins) can down-regulate expression of FLICE-inhibitory protein, making endothelial cells less resistant to Fas-mediated apoptosis (28) .
Although it is possible that the whole antibody used in these experiments could form immune complexes, it is unlikely that this would alter our findings, because immune complex formation would be expected to increase blood-retinal barrier breakdown, an effect not observed in the antiFasL-treated rats. Also, circulating FasL concentrations in serum (∼0.1 ng/ml) would be low compared with anti-FasL concentrations after treatment, reducing the chance of multimeric immune complex formation (C. Benoist, personal communication).
The physiologic significance of our findings is substantiated by the inhibition of diabetic bloodretinal barrier breakdown in vivo by neutralizing anti-FasL antibody. Blood-retinal barrier breakdown results in diabetic macular edema, the most prevalent cause of vision loss in diabetes.
In addition, marked blood-retinal barrier breakdown is a hallmark of the retinal neovascularization of proliferative diabetic retinopathy that can lead to severe visual loss.
Previous work has suggested that alterations of intercellular adhesion molecules such as occludin and ZO-1 might be responsible for the blood-retinal barrier breakdown in diabetic retinopathy by changing pericellular or transcellular fluid transport (25, 29) . Our data suggest that increased blood-retinal barrier breakdown in diabetes may be, at least in part, the result of direct induction of apoptosis in the vascular endothelium.
Endothelial cell death is a hallmark of diabetic retinopathy. Its occurrence underlies the formation of acellular (devitalized) capillaries, lesions that produce irreversible retinal ischemia. As first proposed by others (24), we hypothesize that the chronic low-grade endothelial cell death of early diabetes is repairable, but as diabetes progresses, the vascular endothelium reaches its Hayflick number and can no longer repair its damaged endothelial lining. Acellular capillary formation ensues at this point, leading to marked retinal VEGF up-regulation and transition to the proliferative stage of retinopathy. The current data provide an important molecular insight regarding the early pathogenesis of this process.
In conclusion, our data demonstrate that diabetes increases the susceptability of the retinal vasculature to Fas-mediated apoptosis and that diabetes-induced up-regulation of FasL on the leukocyte cell surface causes injury, apoptosis, and death of retinal vascular endothelial cells, resulting in blood-retinal barrier breakdown. This mechanistic explanation implies that if safe and efficacious inhibitors of the retinal Fas-FasL system can be developed, they might prove beneficial in preventing this sight-threatening complication of diabetic retinopathy. Retinae from rats diabetic for 2-wk (upper panels) and control rats (lower panels) were evaluated by dual-label immunohistochemistry, using antibodies to Fas (left panels) and endothelial selective CD-31 (right panels). 
